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Thioredoxin Reductase 2 (Txnrd2) Regulates Mitochondrial Integrity
in the Progression of Age-Related Heart Failure
Jun Yoshioka, MD, PhD
A ging is a multifactorial process that is characterized bythe accumulation of damaged cellular components and
that leads progressively to deterioration of biological func-
tions.1 Recently, increased cellular production of reactive
oxygen species (ROS) and decreased removal of oxidized
proteins have been implicated in the aging process.2 During
aging, ROS generation is ampliﬁed, leading to the accumula-
tion of oxidative damage to cells. Such enhancements can
result from the lack of proportional regulation of antioxidant
systems in the body.
Mitochondria are a central source of ROS under stressful
energetic and redox conditions: They produce 85% to 90% of
cellular ROS.3 Mitochondria are the energy-generating
organelles that play crucial roles in the fundamental cellular
processes, including supply of metabolic intermediates,
calcium homeostasis, and apoptotic signaling. During mito-
chondrial respiration, redox reactions occur, but a small
percentage of electrons do not complete the series of
passages through the electron transport chain and thus
generate ROS mainly at complexes I and III of the electron
transport chain. Because of the high reliance of cardiomy-
ocytes on mitochondrial energy metabolism, the heart is
always challenged by a considerable burden of ROS through-
out the lifespan. Morphological and functional alterations of
mitochondria have been observed in the aged myocardium,
including mitochondrial swelling, matrix derangement, and
loss of cristae.4 Dysfunctional mitochondria produce less ATP,
release greater amounts of ROS, and have a higher propensity
to trigger apoptosis during cardiac aging.5 These observations
emphasize the importance of understanding the mechanism
that links mitochondrial dysfunction and age-related heart
diseases.
The mitochondrial thioredoxin system is the major H2O2
scavenger providing a primary defense against ROS produced
by the mitochondrial respiratory chain. The mitochondrial
thioredoxin system is composed of thioredoxin 2, peroxire-
doxin 3 (thioredoxin peroxidase 2), and thioredoxin reductase
2 (Txnrd2). Thioredoxin 2 is localized to the mitochondrial
matrix and found at the highest levels in metabolically active
tissues such as the heart.6 Peroxiredoxin 3 contains a
mitochondrial localization sequence, is found exclusively in
the mitochondrion, and uses thioredoxin 2 as the electron
donor to detoxify H2O2 generated by the mitochondrial
metabolism. Txnrd2 is a selenocysteine-containing homod-
imeric ﬂavoenzyme necessary for maintaining thioredoxin 2 in
its reduced state using electrons from NADPH. Txnrd2
contains a typical mitochondrial import sequence that keeps
the protein within the mitochondria.7 Consequently, Txnrd2
governs the reducing activity of thioredoxin 2 in mitochondria,
thereby controlling cellular redox balance through peroxire-
doxin 3 in the mammalian heart.8 It has become more clear
that aging is associated with signiﬁcant downregulation of
Trxrd2 expressions in the mammalian heart9; however, an
important question is whether Trxrd2 represents an active
protective response in the aging heart.
In this issue of Journal of the American Heart Association
(JAHA), Kiermayer et al provided remarkably important
insights regarding a crucial role of Txnrd2 in the aging
heart.10 The important functions of Txnrd2 in the aging heart
are not totally surprising considering the indispensability of
Txnrd2 for embryonic cardiac development11; however,
elegant work by Kiermayer et al further detailed how Txnrd2
preserves the mitochondrial integrity, redox homeostasis, and
cardiac function in the aging heart. With their studies, they
demonstrated that inducible cardiomyocyte-speciﬁc deletion
of Txnrd2 caused left ventricular hypertrophy and dysfunction
with reduced systemic blood pressure in aged mice but not in
younger mice. These changes in the aged Txnrd2 knockout
hearts appear to be attributed to severe mitochondrial
degeneration (eg, loss of cristae), leading to progressive
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heart failure with consequent bioenergic insufﬁciency during
aging.
Several important molecular ﬁndings emerged from this
study (Figure). First, deletion of Txnrd2 in the heart induced
protein stabilization of the a subunit of hypoxia-inducible
factor 1 (HIF-1a). HIF-1 is a master transcription factor that
controls cellular metabolism for adaptation to low oxygen
availability.12 Under normoxia, HIF-1a undergoes rapid pro-
teasomal degradation. When oxygen is low, HIF-1a is
stabilized and translocated to the nucleus, where it stimulates
transcription of genes encoding glucose transporters and
enzymes of glycolysis and negatively regulates tricarboxylic
acid cycle enzymes.13 It has been known that even under
normoxic conditions, ROS can inhibit HIF-1a degradation and
increase HIF-1a expression.14 In this study, by using an
integrated approach, the authors demonstrated that a loss of
Txnrd2 induced HIF-1–mediated adaptive and protective
metabolic responses under normoxia. These responses
included transcriptional changes of HIF-1 target genes such
as glucose transporter 1 (GLUT1) and a signiﬁcant decrease in
fatty acid catabolism. Mitochondria from the aged Txnrd2
knockout mice consumed less oxygen, suggesting reduced
oxidative phsophorylation. Interestingly, despite reduced
oxidative phosphorylation, the ATP content in the whole
myocardium did not change in Txnrd2 knockout hearts. Given
the fact that HIF-1 is activated, it is tempting to speculate that
the HIF-1–induced glycolytic pathway compensates for the
limited energy supply from the tricarboxylic acid cycle. A
metabolic shift from oxidative phosphorylation to glycolysis
makes sense under severe oxidative stress in mitochondria
because the glycolytic pathway could provide key intermedi-
ates for de novo synthesis of nucleotides, amino acids, and
lipid, in which the oxidative pentose phosphate pathway
produces NADPH to counter oxidative stress.15
Second, the authors demonstrated that the autophagic
pathway was activated in Txnrd2-deﬁcient mitochondria,
whereas cardiomyocyte apoptosis was not signiﬁcantly
induced by deletion of Txnrd2 in the aging heart. Autophagy
or mitophagy has been shown to degrade dysfunctional
mitochondria, limiting ROS production and eliminating oxida-
tively damaged organelles and protein aggregates.16 Under
conditions of oxidative stress, autophagy can be activated to
promote the release of recycled nutrients into the microen-
vironment, and these nutrients may be used by adjacent cells
to support their survival.17 During aging, continuous consti-
tutive autophagy is necessary for maintaining intact cardiac
structure and function.18 Based on these pieces of evidence,
it is reasonable to hypothesize that the housekeeping
property of autophagy plays a protective role as a compen-
satory mechanism in the aged Txnrd2 knockout cardiomy-
ocytes to antagonize cell death. Although not addressed in
this paper, the induction of autophagy might be dependent on
the stress response of HIF-1, which is speciﬁcally stabilized by
deletion of Txnrd2. This is supported by the observation that
HIF-1–dependent activation of autophagy and glycolysis
greatly enhances anabolic growth in cancer cells,19 linking
activation of autophagic and glycolytic pathways with cell
survival.
Finally, further mechanical questions remain to be
addressed to fully understand the role of Txnrd2 in age-
related heart failure. Is the function of Txnrd2, for example,
mediated solely through mitochondrial thioredoxin 2 activity
in the aging heart or is another pathway involved? It seems
that both thioredoxin 2 and Txnrd2 are essential for
endogenous cardioprotection in a similar way.20 Thioredoxin
2 cardiac knockout mice share many speciﬁc phenotypes with
the aged Txnrd2 cardiac knockout mice, including a progres-
sive loss of mitochondrial integrity and function20; however,
thioredoxin reductase is a promiscuous enzyme capable of
interacting with many other endogenous proteins and
substrates including lipoic acid, lipid hydroperoxides, the
cytotoxic peptide NK-lysin, vitamin K3, dehydroascorbic acid,
the ascorbyl free radical, and tumor suppressor p53.21
Because Txnrd2 can reduce bulky proteins to small molecules,
mechanisms may include multiple signaling pathways to













Figure. A possible regulatory mechanism by which Txnrd2
inactivation leads to the progression of age-related heart failure. A
prominent hypothesis of Txnrd2 inactivation postulates that
accumulating mitochondrial damage by increased generation of
ROS results in progressive mitochondrial degeneration with
consequent bioenergic insufﬁciency and cardiomyocyte death
during aging. Txnrd2 inactivation induces stabilization of the a
subunit of HIF-1 and transcriptional activation of HIF-1. The
HIF-1–driven metabolic adaptation and increased autophagy may
be necessary for resistance to mitochondrial oxidative damage
and an energy crisis in the aged cardiomyocytes. These pathways
suggest integrated regulation of the mitochondrial thioredoxin
system that confers resistance to oxidative stress in cardiac
senescence. HIF-1 indicates hypoxia-inducible factor 1; ROS,
reactive oxygen species; Txnrd2, thioredoxin reductase 2.
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Kiermayer et al described a previously unrecognized meta-
bolic response to mitochondrial ROS in the aging heart. Their
ﬁndings revealed signiﬁcant redox adaptations to cardiac aging
and uncovered a novel role of Txnrd2 as amechanism to control
morphological and functional integrity of mitochondria for
proper metabolic arrangements. Although these data warrant
further research on the role of Txnrd2, the work by Kiermayer
et al provides an important perspective regarding the relation-
ship between evolutionarily conserved mechanisms of mito-
chondrial metabolism and cardiac senescence.
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